Megestrol Acetate Should NOT Be Used for Metastatic Prostate Cancer Treatment
Megestrol acetate (Megace) is not recommended for patients with metastatic prostate cancer, as it is not included in current evidence-based treatment guidelines and has demonstrated minimal to no therapeutic benefit in this population.
Guideline-Based Recommendations
The most recent ASCO 2025 guidelines for metastatic castration-resistant prostate cancer (mCRPC) provide comprehensive treatment recommendations but notably exclude megestrol acetate entirely 1. The recommended systemic therapies include:
- Androgen receptor pathway inhibitors (ARPIs: enzalutamide, abiraterone)
- PARP inhibitors for BRCA1/2 alterations
- Chemotherapy (docetaxel, cabazitaxel)
- Radiopharmaceuticals (radium-223, 177Lu-PSMA-617)
- Sipuleucel-T
Similarly, the 2023 ESMO guidelines make no mention of megestrol acetate as a treatment option for any stage of metastatic prostate cancer 2. This absence from major international guidelines is telling—if megestrol acetate had meaningful efficacy, it would be included.
Evidence of Limited Efficacy
The research evidence consistently demonstrates poor activity:
- A randomized Cancer and Leukemia Group B trial comparing standard dose (160 mg/day) versus high dose (640 mg/day) megestrol acetate showed no survival benefit (median survival 11.2 vs 12.1 months, not significant) and minimal response rates (only 2-3% partial responses) 3
- A retrospective study found only a 14% response rate with median time to progression of just 2 months, leading authors to conclude they "cannot recommend megestrol acetate as an effective second-line therapy" 4
Safety Concerns Specific to Prostate Cancer
The FDA labeling reveals concerning preclinical data: megestrol acetate caused feminization of male fetuses and impaired reproductive capability in male offspring in animal studies 5. More critically, there is a case report of rising PSA levels associated with low-dose megestrol acetate (20 mg twice daily) used for hot flash control, with PSA declining after discontinuation 6. This suggests potential tumor stimulation even at low doses.
The Only Appropriate Context
Megestrol acetate's FDA-approved indication is for anorexia, cachexia, or unexplained weight loss in AIDS patients—not cancer treatment 5. One study in CRPC patients receiving docetaxel chemotherapy found that megestrol acetate used specifically for cachexia palliation did not worsen disease-specific survival 7. However, this addresses symptom management, not cancer treatment.
Clinical Algorithm
For metastatic prostate cancer treatment:
- Do NOT use megestrol acetate as anticancer therapy
- Follow ASCO/ESMO guideline-recommended agents based on prior treatments and molecular alterations 1, 2
For cachexia in metastatic prostate cancer:
- Consider megestrol acetate ONLY for appetite stimulation/weight gain in severely cachectic patients already receiving appropriate anticancer therapy
- Monitor PSA levels closely for any increase suggesting tumor stimulation
- Discontinue if PSA rises after initiation
Common pitfall to avoid: Do not confuse megestrol acetate's historical use in hormone-sensitive disease (outdated) with current evidence-based practice. The therapeutic landscape has evolved dramatically with ARPIs, PARP inhibitors, and radiopharmaceuticals that provide actual survival benefits.